Literature DB >> 8328778

Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.

J Fung-Tomc1, B Kolek, D P Bonner.   

Abstract

The effects of ciprofloxacin on the rates of development of low-level resistance to other antibiotics were determined in vitro. Three methicillin-resistant Staphylococcus aureus and two Pseudomonas aeruginosa clinical strains were grown overnight in Mueller-Hinton broth with or without subinhibitory concentrations (1/2, 1/4, and 1/8 MICs) of ciprofloxacin or an aminoglycoside and then quantitatively plated onto medium containing 4 or 8 times the MICs of various antibiotics. The spontaneous mutational frequencies were determined and compared with those of cells not exposed to ciprofloxacin. Exposure of methicillin-resistant S. aureus strains to ciprofloxacin resulted in a > 100-fold increase in the isolation of variants with decreased susceptibilities to ciprofloxacin, tetracycline, imipenem, fusidic acid, and gentamicin, but not vancomycin. Likewise, a > 100-fold increase in the isolation of variants with decreased susceptibilities to ciprofloxacin and imipenem (35-fold) in P. aeruginosa A21213 was observed, and a > 100-fold increase in the isolation of variants with decreased susceptibilities to ciprofloxacin, amikacin, and cefepime in P. aeruginosa A22379 was observed. On the other hand, exposure of these strains to an aminoglycoside did not influence the development of resistance to nonaminoglycoside drugs. These results indicate that exposure to subinhibitory levels of ciprofloxacin can promote the development of low-level resistance to antibiotics with different modes of action.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8328778      PMCID: PMC187955          DOI: 10.1128/AAC.37.6.1289

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  48 in total

1.  4-Quinolone resistant staphylococci.

Authors:  M S Dryden; H A Ludlam; I Phillips
Journal:  J Antimicrob Chemother       Date:  1990-09       Impact factor: 5.790

2.  Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus.

Authors:  K Ubukata; N Itoh-Yamashita; M Konno
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  Outer membrane changes in quinolone resistant Pseudomonas aeruginosa.

Authors:  Z S Hashmi; J M Smith
Journal:  J Antimicrob Chemother       Date:  1991-09       Impact factor: 5.790

4.  Phenotypic characterization of quinolone-resistant mutants of Enterobacteriaceae selected from wild type, gyrA type and multiply-resistant (marA) type strains.

Authors:  L J Piddock; M C Hall; R N Walters
Journal:  J Antimicrob Chemother       Date:  1991-08       Impact factor: 5.790

5.  Ciprofloxacin in the treatment of infections caused by gentamicin-resistant gram-negative bacteria.

Authors:  S Mehtar; Y Drabu; P Blakemore
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

6.  Cross-resistance of nalidixic acid resistant Enterobacteriaceae to new quinolones and other antimicrobials.

Authors:  L J Piddock; J M Diver; R Wise
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

7.  Induction of the SOS response by new 4-quinolones.

Authors:  I Phillips; E Culebras; F Moreno; F Baquero
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

8.  Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin.

Authors:  G Rådberg; L E Nilsson; S Svensson
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

9.  Spontaneous and mutagen-induced deletions: mechanistic studies in Salmonella tester strain TA102.

Authors:  D E Levin; L J Marnett; B N Ames
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

10.  Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12.

Authors:  K Hirai; H Aoyama; S Suzue; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

View more
  15 in total

Review 1.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

2.  Effect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators.

Authors:  Natalia R Morero; Mariela R Monti; Carlos E Argaraña
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

3.  Role of phage-antibiotic combination in reducing antibiotic resistance in Staphylococcus aureus.

Authors:  Ara Jo; Jeongjin Kim; Tian Ding; Juhee Ahn
Journal:  Food Sci Biotechnol       Date:  2016-08-31       Impact factor: 2.391

4.  Ciprofloxacin induction of a susceptibility determinant in Pseudomonas aeruginosa.

Authors:  Michelle D Brazas; Robert E W Hancock
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 5.  Risk factors for acquisition of multiply drug-resistant gram-negative bacteria.

Authors:  I M Gould
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

6.  Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group.

Authors:  J Lipman; J Scribante; A G Gous; H Hon; S Tshukutsoane
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

7.  The complete genome sequence of Xanthomonas albilineans provides new insights into the reductive genome evolution of the xylem-limited Xanthomonadaceae.

Authors:  Isabelle Pieretti; Monique Royer; Valérie Barbe; Sébastien Carrere; Ralf Koebnik; Stéphane Cociancich; Arnaud Couloux; Armelle Darrasse; Jérôme Gouzy; Marie-Agnès Jacques; Emmanuelle Lauber; Charles Manceau; Sophie Mangenot; Stéphane Poussier; Béatrice Segurens; Boris Szurek; Valérie Verdier; Matthieu Arlat; Philippe Rott
Journal:  BMC Genomics       Date:  2009-12-17       Impact factor: 3.969

8.  Role of lon, an ATP-dependent protease homolog, in resistance of Pseudomonas aeruginosa to ciprofloxacin.

Authors:  Michelle D Brazas; Elena B M Breidenstein; Joerg Overhage; Robert E W Hancock
Journal:  Antimicrob Agents Chemother       Date:  2007-09-24       Impact factor: 5.191

9.  Mycobacterium tuberculosis DNA repair in response to subinhibitory concentrations of ciprofloxacin.

Authors:  D M O'Sullivan; J Hinds; P D Butcher; S H Gillespie; T D McHugh
Journal:  J Antimicrob Chemother       Date:  2008-09-16       Impact factor: 5.790

10.  Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.

Authors:  Lauren Becnel Boyd; Merry J Maynard; Sonia K Morgan-Linnell; Lori Banks Horton; Richard Sucgang; Richard J Hamill; Javier Rojo Jimenez; James Versalovic; David Steffen; Lynn Zechiedrich
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.